Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.0
7.8
Journals
Vaccines
Special Issues
The Health Economic Value of Vaccines
share announcement

The Health Economic Value of Vaccines

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Human Vaccines and Public Health".

Deadline for manuscript submissions: closed (31 January 2024) | Viewed by 3088

Special Issue Editors

Prof. Dr. Lotte Steuten

E-Mail Website
Guest Editor
1. Office of Health Economics, London SW1E 6QT, UK
2. City Health Economics Centre (CHEC), City, University of London, London EC1V 0HB, UK
Interests: vaccines; health economics; cost-effectiveness; health technology assessment; decision analysis; health care policy
Prof. Dr. Maarten J. Postma

E-Mail Website
Guest Editor
1. Department of Health Sciences, University Medical Centre Groningen, University of Groningen, NL 9713 GZ Groningen, The Netherlands
2. Department of Economics, Econometrics & Finance, Faculty of Economics & Business, University of Groningen, NL 9713 GZ Groningen, The Netherlands
Interests: vaccines; global health; health technology assessment; cost-effectiveness; health economics
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The health economic value of vaccines has received increasing attention over the last couple of years due to the COVID-19 pandemic, but is not always comprehensively understood for other non-COVID vaccines. Alleviating (seasonal) capacity pressure on healthcare systems, keeping young as well as elderly populations as healthy as possible, tackling antimicrobial resistance, and maintaining a healthy and productive workforce are just a few examples of the broader healthcare and societal impacts of vaccination programs. Health economic evaluation plays a key role in quantifying the broader value of vaccines to inform healthcare policy and resource allocation decisions, and its methods are evolving. This Special Issue aims to provide an overview of the recent developments in this area from theoretical, methodological, and practical (illustrations) angles. 

Prof. Dr. Lotte Steuten
Prof. Dr. Maarten J. Postma
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • vaccines
  • health economics
  • cost-effectiveness
  • health technology assessment
  • decision analysis
  • health care policy
  • procurement

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Other

16 pages, 1430 KiB  
Article
Influenza Vaccination Implementation in Sri Lanka: A Cost-Effectiveness Analysis
by Coralei E. Neighbors, Evan R. Myers, Nayani P. Weerasinghe, Gaya B. Wijayaratne, Champica K. Bodinayake, Ajith Nagahawatte, L. Gayani Tillekeratne and Christopher W. Woods
Vaccines 2023, 11(5), 932; https://doi.org/10.3390/vaccines11050932 - 03 May 2023
Viewed by 1549
Abstract
Influenza causes an estimated 3 to 5 million cases of severe illness annually, along with substantial morbidity and mortality, particularly in low- and middle-income countries (LMICs). Currently, Sri Lanka has no influenza vaccination policies and does not offer vaccination within the public healthcare [...] Read more.
Influenza causes an estimated 3 to 5 million cases of severe illness annually, along with substantial morbidity and mortality, particularly in low- and middle-income countries (LMICs). Currently, Sri Lanka has no influenza vaccination policies and does not offer vaccination within the public healthcare sector. Therefore, we performed a cost-effectiveness analysis of influenza vaccine implementation for the Sri Lankan population. We designed a static Markov model that followed a population cohort of Sri Lankans in three age groups, 0–4, 5–64, and 65+ years, through two potential scenarios: trivalent inactivated vaccination (TIV) and no TIV across twelve-monthly cycles using a governmental perspective at the national level. We also performed probabilistic and one-way sensitivity analyses to identify influential variables and account for uncertainty. The vaccination model arm reduced influenza outcomes by 20,710 cases, 438 hospitalizations, and 20 deaths compared to no vaccination in one year. Universal vaccination became cost-effective at approximately 98.01% of Sri Lanka’s 2022 GDP per capita (incremental cost-effectiveness ratio = 874,890.55 Rs/DALY averted; 3624.84 USD/DALY averted). Results were most sensitive to the vaccine coverage in the 5–64-year-old age group, the cost of the influenza vaccine dose in the 5–64-years-old age group, vaccine effectiveness in the under-5-years-old age group, and the vaccine coverage in the under-5-years-old age group. No value for a variable within our estimated ranges resulted in ICERs above Rs. 1,300,000 (USD 5386.15) per DALY adverted. Providing influenza vaccines was considered highly cost-effective compared to no vaccines. However, large-scale national studies with improved data are needed to better inform estimates and determine the impact of vaccination implementation. Full article
(This article belongs to the Special Issue The Health Economic Value of Vaccines)
►▼ Show Figures

Figure 1

Other

Jump to: Research

10 pages, 274 KiB  
Opinion
New Vaccine Platforms—Novel Dimensions of Economic and Societal Value and Their Measurement
by Philip O. Buck, Dumingu Aparna Gomes, Ekkehard Beck, Noam Kirson, Matthew Mattera, Stuart Carroll, Bernhard Ultsch, Kavisha Jayasundara, Mathieu Uhart and Louis P. Garrison, Jr.
Vaccines 2024, 12(3), 234; https://doi.org/10.3390/vaccines12030234 - 24 Feb 2024
Viewed by 1029
Abstract
The COVID-19 pandemic’s dramatic impact has been a vivid reminder that vaccines—especially in the context of infectious respiratory viruses—provide enormous societal value, well beyond the healthcare system perspective which anchors most Health Technology Assessment (HTA) and National Immunization Technical Advisory Group (NITAG) evaluation [...] Read more.
The COVID-19 pandemic’s dramatic impact has been a vivid reminder that vaccines—especially in the context of infectious respiratory viruses—provide enormous societal value, well beyond the healthcare system perspective which anchors most Health Technology Assessment (HTA) and National Immunization Technical Advisory Group (NITAG) evaluation frameworks. Furthermore, the development of modified ribonucleic acid-based (mRNA-based) and nanoparticle vaccine technologies has brought into focus several new value drivers previously absent from the discourse on vaccines as public health interventions such as increased vaccine adaptation capabilities, the improved ability to develop combination vaccines, and more efficient vaccine manufacturing and production processes. We review these novel value dimensions and discuss how they might be measured and incorporated within existing value frameworks using existing methods. To realize the full potential of next-generation vaccine platforms and ensure their widespread availability across populations and health systems, it is important that value frameworks utilized by HTAs and NITAGs properly reflect the full range of benefits for population health and well-being and cost efficiencies that these new vaccines platforms provide. Full article
(This article belongs to the Special Issue The Health Economic Value of Vaccines)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop